The message is the glass is half full, ... The drugs work but they are not satisfactory to many patients, and three-quarters of the people in our study voted with their feet and discontinued the drugs.

what works for one person may not work for another.

This is a rapidly evolving field, and it's bringing a lot of different disciplines together. Unlike drugs or radiation, which are given to the patient, do their damage, and leave, what we're doing is asking the patient's own immune system to mount an attack on the cancer. It's very, very different from standard chemotherapy.

These results indicated that this class of drugs may prove effective in treating HIV patients with dementia.

We don't want someone skipping out saying, 'I took all sorts of drugs and I'm negative,' or 'I can continue to do what I was doing.' It's really an opportunity to do some prevention work.

It is critically important as we make investment decisions, bring new drugs to market, that we know what the rules of the game are so that we can have a predictable, transparent intellectual property system.